Amanote Research
Register
Sign In
Breast-Cancer Adjuvant Therapy With Zoledronic Acid
New England Journal of Medicine
- United States
doi 10.1056/nejmc1113049
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
January 12, 2012
Authors
Unknown
Publisher
Massachusetts Medical Society
Related search
Innegligible Musculoskeletal Disorders Caused by Zoledronic Acid in Adjuvant Breast Cancer Treatment: A Meta-Analysis
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Adjuvant Zoledronic Acid Reduces Fractures in Breast Cancer Patients; An AZURE (BIG 01/04) Study
European Journal of Cancer
Cancer Research
Oncology
Bisphosphonates as Adjuvant Therapy for Breast Cancer
Women's Health
Medicine
Zoledronic Acid Inhibits Macrophage/Microglia-Assisted Breast Cancer Cell Invasion
Oncotarget
Oncology
PCN67 Cost Effectiveness of Zoledronic Acid (ZOL) in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole From German and Italian Perspectives
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
Breast Care
Surgery
Oncology
Adjuvant Therapy After Preoperative Treatment for Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Pretreatment of Breast Cancer Cells With Doxorubicin Facilitates the Subsequent Uptake of Zoledronic Acid
Breast Cancer Research
Cancer Research
Oncology
Long Term Adjuvant Therapy for Primary Breast Cancer
BMJ